EFFICACY AND SAFETY OF CM310 IN MODERATE-TO-SEVERE ATOPIC DERMATITIS: RESULTS FROM A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B TRIAL IN CHINA

被引：0
|
作者：
Zhang, Jianzhong [1 ]
Yang, Bin [2 ]
Li, Jingyi [3 ]
Ding, Yangfeng [4 ]
Wu, Liming [5 ]
Zhang, Litao [6 ]
Wang, Jinyan [7 ]
Zhu, Xiaohong [8 ]
Zhang, Furen [9 ]
Tao, Xiaohua [10 ]
Li, Yumei [11 ]
Zhang, Chunlei [12 ]
Li, Linfeng [13 ]
Lu, Jianyun [14 ]
Diao, Qingchun [15 ]
Lu, Qianjin [16 ]
Man, Xiaoyong [17 ]
Li, Fuqiu [18 ]
Xia, Xiujuan [19 ]
Cheng, Hao [20 ]
Zhao, Yan [1 ]
Chen, Bo [21 ]
Yan, Jinchun [21 ]
Zhao, Guoqing [21 ]
Jia, Yingmin [21 ]
机构：
[1] Peking Univ, Dept Dermatol, Peoples Hosp, Beijing, Peoples R China
[2] Southern Med Univ, Dept Dermatol, Dermatol Hosp, Guangzhou, Peoples R China
[3] Sichuan Univ, Dept Dermatol, West China Sch, Chengdu, Peoples R China
[4] Shanghai Skin Dis Hosp, Dept Dermatol, Shanghai, Peoples R China
[5] Hangzhou First Peoples Hosp, Dept Dermatol, Hangzhou, Peoples R China
[6] Tianjin Acad Tradit Chinese Med Affiliated Hosp, Dept Dermatol, Tianjin, Peoples R China
[7] Univ Chinese Acad Sci, Dept Dermatol, Ningbo Huamei Hosp, Ningbo, Peoples R China
[8] Wuxi Second Peoples Hosp, Dept Dermatol, Wuxi, Jiangsu, Peoples R China
[9] Shandong First Med Univ, Dept Dermatol, Dermatol Hosp, Jinan, Peoples R China
[10] Zhejiang Prov Peoples Hosp, Dept Dermatol, Hangzhou, Peoples R China
[11] Jiangsu Univ, Dept Dermatol, Affiliated Hosp, Zhenjiang, Jiangsu, Peoples R China
[12] Peking Univ Third Hosp, Dept Dermatol, Beijing, Peoples R China
[13] Capital Med Univ, Dept Dermatol, Beijing Friendship Hosp, Beijing, Peoples R China
[14] Cent South Univ, Dept Dermatol, Xiangya Hosp 3, Changsha, Peoples R China
[15] Chongqing Tradit Chinese Med Hosp, Dept Dermatol, Chongqing, Peoples R China
[16] Cent South Univ, Dept Dermatol, Xiangya Hosp 2, Changsha, Peoples R China
[17] Zhejiang Univ, Dept Dermatol, Sch Med, Affiliated Hosp 2, Hangzhou, Peoples R China
[18] Jilin Univ, Dept Dermatol, Hosp 2, Changchun, Peoples R China
[19] Yantai Yuhuangding Hosp, Dept Dermatol, Yantai, Peoples R China
[20] Zhejiang Univ, Dept Dermatol, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Peoples R China
[21] Keymed Biosci Chengdu Co Ltd, Clin Dept, Chengdu, Peoples R China
来源：
ACTA DERMATO-VENEREOLOGICA | 2022年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
OL.35
引用
收藏
页码：20 / 20
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial
    Zhao, Yan
    Zhang, Jianzhong
    Yang, Bin
    Li, Jingyi
    Ding, Yangfeng
    Wu, Liming
    Zhang, Litao
    Wang, Jinyan
    Zhu, Xiaohong
    Zhang, Furen
    Tao, Xiaohua
    Li, Yumei
    Zhang, Chunlei
    Li, Linfeng
    Lu, Jianyun
    Diao, Qingchun
    Lu, Qianjin
    Man, Xiaoyong
    Li, Fuqiu
    Xia, Xiujuan
    Cheng, Hao
    Jia, Yingmin
    Zhao, Guoqing
    Yan, Jinchun
    Chen, Bo
    [J]. CHINESE MEDICAL JOURNAL, 2024, 137 (02) : 200 - 208
  • [2] Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial
    Zhao Yan
    Zhang Jianzhong
    Yang Bin
    Li Jingyi
    Ding Yangfeng
    Wu Liming
    Zhang Litao
    Wang Jinyan
    Zhu Xiaohong
    Zhang Furen
    Tao Xiaohua
    Li Yumei
    Zhang Chunlei
    Li Linfeng
    Lu Jianyun
    Diao Qingchun
    Lu Qianjin
    Man Xiaoyong
    Li Fuqiu
    Xia Xiujuan
    Cheng Hao
    Jia Yingmin
    Zhao Guoqing
    Yan Jinchun
    Chen Bo
    [J]. 中华医学杂志(英文版), 2024, 137 (02)
  • [3] A phase 2b, randomized, double-blind, placebo-controlled, global study to evaluate the efficacy and safety of ANB032 in the treatment of moderate-to-severe atopic dermatitis
    Ehst, B.
    Silverberg, J.
    Lizzul, P.
    Luu, K.
    Papacharalambous, J.
    Raina, P.
    Randazzo, B.
    Sibley, C.
    Guttman-Yassky, E.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2023, 143 (11) : S347 - S347
  • [4] Early response to upadacitinib in moderate-to-severe atopic dermatitis: Results from a phase 2b randomized, placebo-controlled trial
    Reich, K.
    Guttman-Yassky, E.
    Beck, L. A.
    Hu, X.
    Pangan, A. L.
    Teixeira, H. D.
    [J]. ALLERGY, 2018, 73 : 76 - 76
  • [5] The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study
    Zhao, Y.
    Wu, L.
    Lu, Q.
    Gao, X.
    Zhu, X.
    Yao, X.
    Li, L.
    Li, W.
    Ding, Y.
    Song, Z.
    Liu, L.
    Dang, N.
    Zhang, C.
    Liu, X.
    Gu, J.
    Wang, J.
    Geng, S.
    Liu, Q.
    Guo, Y.
    Dong, L.
    Su, H.
    Bai, L.
    O'Malley, J. T.
    Luo, J.
    Laws, E.
    Mannent, L.
    Ruddy, M.
    Amin, N.
    Bansal, A.
    Ota, T.
    Wang, M.
    Zhang, J.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : 633 - 641
  • [6] EFFICACY AND SAFETY OF DUPILUMAB IN THE TREATMENT OF MODERATE-TO-SEVERE ATOPIC DERMATITIS IN CHINESE ADULTS: A MULTICENTER, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL
    Zhao, Yan
    Wu, Liming
    Lu, Qianjin
    Gao, Xinghua
    Zhu, Xiaohong
    Yao, Xu
    Li, Linfeng
    Li, Wei
    Ding, Yangfeng
    Song, Zhiqiang
    Liu, Lingling
    Dang, Ningning
    Zhang, Chunlei
    Liu, Xiaoming
    Gu, Jun
    Wang, Jinyan
    Geng, Songhai
    Liu, Qunazhong
    Guo, Yifeng
    Lv, Dong
    Ren, Gong
    Yang, Xiumin
    Deng, Danqi
    Li, Shanshan
    Han, Xiuping
    Biao, Shuzhen
    Zheng, Min
    Dong, Li
    Su, Huijuan
    Bai, Lili
    O'Malley, John T.
    Luo, Junxiang
    Zhang, Jianzhong
    [J]. ACTA DERMATO-VENEREOLOGICA, 2021, 101 : 58 - 58
  • [7] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Tyring, Stephen K. K.
    Rich, Phoebe
    Tada, Yayoi
    Beeck, Stefan
    Messina, Izabella
    Liu, Jie
    Huang, Xiaohong
    Shumack, Stephen
    [J]. DERMATOLOGY AND THERAPY, 2023, 13 (02) : 595 - 608
  • [8] Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study
    Stephen K. Tyring
    Phoebe Rich
    Yayoi Tada
    Stefan Beeck
    Izabella Messina
    Jie Liu
    Xiaohong Huang
    Stephen Shumack
    [J]. Dermatology and Therapy, 2023, 13 : 595 - 608
  • [9] Efficacy and Safety of Baricitinb in a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study in Pediatric Patients with Moderate-to-Severe Atopic Dermatitis
    Torrelo, A.
    Rewerska, B.
    Paller, Amy
    Prakash, A.
    Zhu, D.
    Pontes, M.
    Wu, Wen-Shuo
    Eichenfield, Lawrence F.
    Boecker, Ulrike
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 99 - 99
  • [10] UPADACITINIB EFFECT ON PRURITUS IN MODERATE-TO-SEVERE ATOPIC DERMATITIS; FROM A PHASE 2B RANDOMIZED, PLACEBO-CONTROLLED TRIAL
    Beck, L.
    Hong, C.
    Hu, X.
    Chen, S.
    Calimlim, B.
    Teixeira, H.
    Guttman-Yassky, E.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S21 - S21
12345